Unknown

Dataset Information

0

Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants.

ABSTRACT: The emergence of escape variants of SARS-CoV-2 carrying mutations in the spike protein poses a challenge for therapeutic antibodies. Here, we show that through the comprehensive engineering of the variable region of the neutralizing monoclonal antibody 5A6, the engineered antibody, 5A6CCS1, is able to neutralize SARS-CoV-2 variants that escaped neutralization by the original 5A6 antibody. In addition to the improved affinity against variants, 5A6CCS1 was also optimized to achieve high solubility and low viscosity, enabling a high concentration formulation for subcutaneous injection. In cynomolgus monkeys, 5A6CCS1 showed a long plasma half-life and good subcutaneous bioavailability through engineering of the variable and constant region. These data demonstrate that 5A6CCS1 is a promising antibody for development against SARS-CoV-2 and highlight the importance of antibody engineering as a potential method to counteract escape variants.

SUBMITTER: Kuramochi T 

PROVIDER: S-EPMC8932922 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The emergence of escape variants of SARS-CoV-2 carrying mutations in the spike protein poses a challenge for therapeutic antibodies. Here, we show that through the comprehensive engineering of the variable region of the neutralizing monoclonal antibody 5A6, the engineered antibody, 5A6CCS1, is able to neutralize SARS-CoV-2 variants that escaped neutralization by the original 5A6 antibody. In addition to the improved affinity against variants, 5A6CCS1 was also optimized to achieve high solubility  ...[more]

Similar Datasets

Unknown A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
| S-EPMC7803729 | biostudies-literature
Unknown Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
| S-EPMC7723407 | biostudies-literature
Unknown Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.
| S-EPMC5512576 | biostudies-literature
Unknown Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.
| S-EPMC4097068 | biostudies-literature
Unknown Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity.
| S-EPMC7329936 | biostudies-literature
Unknown Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants.
| S-EPMC8308897 | biostudies-literature
Unknown Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
| S-EPMC8651051 | biostudies-literature
Unknown A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
| S-EPMC5520321 | biostudies-other
Unknown Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
| S-EPMC8782626 | biostudies-literature
Unknown Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants.
| S-EPMC9113379 | biostudies-literature